Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04565925 · ClinicalTrials.gov registry record · Phase 2

Sildenafil for Treatment of Urinary Incontinence in Patients With Spinal Cord Injuries

A Phase 2 study of Spinal Cord Injuries and Urinary Incontinence, sponsored by The University of Texas Medical Branch, Galveston.

Recruiting
Registry status
Phase 2
Development phase
24
Enrollment target
2
Study locations

NCT04565925 is a Phase 2 study of Spinal Cord Injuries and Urinary Incontinence that is actively recruiting participants, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 24 participants, below the 61-participant average among 202 other Spinal Cord Injuries trials with a reported enrollment target (61% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04565925, a Phase 2 study of Spinal Cord Injuries and Urinary Incontinence, is actively recruiting participants, sponsored by The University of Texas Medical Branch, Galveston.

RECRUITING
Registry status
Phase 2
Development phase
24 participants
Enrollment target
2
Study locations

Study Summary

The goal of this study is to determine whether administration of sildenafil will decrease urine leakage in patients with spinal cord injuries.

Interventions

  • DRUG Placebo
  • DRUG Sildenafil Citrate

Study Locations (2)

Texas

  • Texas A&M University - College Station
  • University of Texas Medical Branch - Galveston

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2021-07-07
Est. Completion 2026-12-01
Phase Phase 2

What the Registry Record Tells You About NCT04565925

The ClinicalTrials.gov registry entry for NCT04565925 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 61-participant average among 202 other Spinal Cord Injuries trials with a reported enrollment target (61% lower). The listed sponsor is The University of Texas Medical Branch, Galveston, which has 203 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Spinal Cord Injuries appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04565925 reports 2 study locations spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT04565925 about?

NCT04565925 is a clinical study titled "Sildenafil for Treatment of Urinary Incontinence in Patients With Spinal Cord Injuries". The goal of this study is to determine whether administration of sildenafil will decrease urine leakage in patients with spinal cord injuries.

What is the current status of trial NCT04565925?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2021-07-07. Estimated completion is 2026-12-01.

What conditions does trial NCT04565925 study?

This clinical trial studies the following conditions: Spinal Cord Injuries, Urinary Incontinence.

What interventions are being tested in trial NCT04565925?

The interventions under investigation include: Placebo (DRUG), Sildenafil Citrate (DRUG).

Who is sponsoring clinical trial NCT04565925?

This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04565925 being conducted?

This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Spinal Cord Injuries

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.